Predicting sensitivity to azacytidine in non-small cell cancer lines by absence of activating mutations.
John Wrangle(Johns Hopkins University), Malcolm V. Brock(Johns Hopkins University), James Shin(Johns Hopkins University), James G. Herman(UPMC Hillman Cancer Center), Charles M. Rudin(Memorial Sloan Kettering Cancer Center), Cynthia A. Zahnow(Johns Hopkins University), Stephen B. Baylin(Johns Hopkins University), Kirsten Harbom(Johns Hopkins Hospital), Abde M. Abukhdeir(Rush University Medical Center), Kristen Rodgers(Johns Hopkins University), Helai P. Mohammad(Arysta LifeScience (France)), Rosalyn A. Juergens(McMaster University)
Cited by 0
Related Papers
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
Inactivation of the DNA-Repair Gene<i>MGMT</i>and the Clinical Response of Gliomas to Alkylating Agents
|New England Journal of Medicine|2000|2.2k
Incidence and functional consequences of <i>hMLH1</i> promoter hypermethylation in colorectal carcinoma
|Proceedings of the National Academy of Sciences|1998|1.9k